Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Incyte Corp (INCY)

Incyte Corp (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,723,610
  • Shares Outstanding, K 215,067
  • Annual Sales, $ 1,882 M
  • Annual Income, $ 109,490 K
  • 60-Month Beta 1.05
  • Price/Sales 8.85
  • Price/Cash Flow 71.05
  • Price/Book 7.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 0.56
  • Number of Estimates 2
  • High Estimate 0.65
  • Low Estimate 0.48
  • Prior Year 0.20
  • Growth Rate Est. (year over year) +180.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.00 +8.00%
on 09/27/19
81.97 -5.14%
on 09/23/19
-0.78 (-0.99%)
since 09/18/19
3-Month
72.00 +8.00%
on 09/27/19
87.23 -10.86%
on 08/01/19
-3.55 (-4.37%)
since 07/18/19
52-Week
57.00 +36.42%
on 12/24/18
89.30 -12.92%
on 06/24/19
+13.32 (+20.67%)
since 10/18/18

Most Recent Stories

More News
Why the Earnings Surprise Streak Could Continue for Incyte (INCY)

Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

INCY : 77.76 (+0.43%)
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD

Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.

ABBV : 76.46 (+1.76%)
NVS : 86.88 (-0.40%)
GSK : 42.53 (+0.14%)
INCY : 77.76 (+0.43%)
Editas Inks Deal for Gene Editing Neurological Disease Drugs

Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.

AGN : 173.60 (+0.64%)
INCY : 77.76 (+0.43%)
EDIT : 19.73 (-3.05%)
CELG : 102.95 (+1.13%)
Novavax Begins Phase III Study on Influenza Vaccine Candidate

Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.

SNY : 46.17 (-0.71%)
INCY : 77.76 (+0.43%)
NVAX : 4.49 (-3.02%)
NCNA : 6.80 (+2.26%)
Novavax Begins Phase III Study on Influenza Vaccine Candidate

Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.

SNY : 46.17 (-0.71%)
INCY : 77.76 (+0.43%)
NVAX : 4.49 (-3.02%)
NCNA : 6.80 (+2.26%)
Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi(R)) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

--- Full results expected to be submitted to an upcoming scientific meeting

INCY : 77.76 (+0.43%)
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA

Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.

BAYRY : 18.1900 (-0.49%)
INCY : 77.76 (+0.43%)
RARE : 42.71 (-2.69%)
RGNX : 37.75 (-3.28%)
Alexion Pharm has the Best Relative Performance in the Biotechnology Industry (ALXN , INCY , REGN , AMGN , BIIB )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ALXN : 98.41 (-1.58%)
INCY : 77.76 (+0.43%)
REGN : 300.19 (-0.46%)
Blueprint Medicines' Avapritinib Grows to Curb Revenue Reliance

The NDA for Blueprint Medicines' (BPMC) lead candidate avapritinib is currently under review in the United States. Heavy reliance on partners for collaboration revenues remains a concern.

BAYRY : 18.1900 (-0.49%)
RHHBY : 36.8100 (+0.68%)
BPMC : 75.15 (+0.48%)
INCY : 77.76 (+0.43%)
Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo

Incyte (Nasdaq:INCY) today announces positive 52-week results from its randomized, double-blind, dose-ranging, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor...

INCY : 77.76 (+0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade INCY with:

Business Summary

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis...

See More

Key Turning Points

2nd Resistance Point 80.26
1st Resistance Point 79.01
Last Price 77.76
1st Support Level 76.88
2nd Support Level 76.00

See More

52-Week High 89.30
Last Price 77.76
Fibonacci 61.8% 76.96
Fibonacci 50% 73.15
Fibonacci 38.2% 69.34
52-Week Low 57.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar